imatinib mesylate has been researched along with Thromboembolism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boknäs, N; Deb, S; Lotfi, K; Ramström, S; Sjöström, C; Tharmakulanathan, A | 1 |
| Grossmann, P; Laco, J; Melichar, B; Slovácek, L; Vanecek, T | 1 |
2 other study(ies) available for imatinib mesylate and Thromboembolism
| Article | Year |
|---|---|
Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?
Topics: Adult; Aniline Compounds; Blood Platelets; Dasatinib; Dose-Response Relationship, Drug; Female; Flow Cytometry; Healthy Volunteers; Hemorrhage; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Nitriles; Platelet Activation; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Thrombin; Thromboembolism; Young Adult | 2020 |
Fatal venous thrombembolism complicating imatinib therapy in a patient with metastatic gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Autopsy; Benzamides; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Thromboembolism | 2006 |